Saluda Medical, Inc. (ASX: SLD), an American commercial-stage medical device company, said on Thursday that its next-generation EVA Sensing Technology has received CE certification for commercialisation in Europe, with recognition of this approval in Australia.
The approval follows US Food and Drug Administration clearance granted in December 2024.
EVA builds on the Evoke System, a closed-loop spinal cord stimulation device that reads and responds to evoked compound action potentials in real time, with the goal of enabling personalised therapy and optimised patient outcomes.
The technology automates manual programming and is designed to objectively scan and analyse a patient's spinal cord to deliver therapy with greater precision, reducing clinical guesswork.
Saluda Medical plans a limited commercial release in Europe and Australia in the first calendar quarter of 2026, followed by a full commercial launch later in the year.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval